Bristol-Myers Squibb Company (BMY) Begins Selling Its Psoriasis Medication Sotyktu Directly to Cash-Paying U.S. Customers

With significant upside potential, Bristol-Myers Squibb Company (NYSE:BMY) secures a spot on our list of the 20 NYSE Stocks with the Lowest P/E Ratios.

Bristol-Myers Squibb Company (NYSE:BMY) announced on September 25, 2025, that it would begin selling its psoriasis medication Sotyktu directly to cash-paying U.S. customers at a price more than 80% lower than its list price, reducing monthly costs from $6,828 to around $950. Targeting uninsured and underinsured patients, the program launched in January via the new BMS Patient Connect platform, bypassing traditional pharmacy benefit managers and insurers.

This move followed the Trump administration’s “most-favored-nation” policy, which increased pressure on pharmaceutical companies to align U.S. drug prices with those abroad. Bristol-Myers Squibb Company (NYSE:BMY) also announced on September 22, 2025, that it would introduce a new medication for schizophrenia.

Bristol-Myers Squibb Company (NYSE:BMY) is a global biopharmaceutical firm engaged in the discovery, development, manufacturing, and marketing of therapies across oncology, hematology, immunology, cardiovascular disease, neuroscience, and other therapeutic areas. It is one of the Stocks with Low PE Ratio.

While we acknowledge the potential of BMY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 15 Stocks That Will Benefit From AI and 12 Best Quantum Computing Stocks to Buy According to Wall Street Analysts.

Disclosure: None.